Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.

about

Concurrent Inhibition of Neurosphere and Monolayer Cells of Pediatric Glioblastoma by Aurora A Inhibitor MLN8237 Predicted Survival Extension in PDOX models.

Item

http://www.wikidata.org/entity/Q49791882

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@en

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@nl

type

Item

label

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@en

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@nl

prefLabel

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@en

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@nl

P1476

Concurrent Inhibition of Neuro ...... ival Extension in PDOX models.

@en

P2093

Adekunle M Adesina

http://www.w3.org/2001/XMLSchema#string

Debra Liao

http://www.w3.org/2001/XMLSchema#string

Frank K Braun

http://www.w3.org/2001/XMLSchema#string

Frank Y Lin

http://www.w3.org/2001/XMLSchema#string

Holly Lindsay

http://www.w3.org/2001/XMLSchema#string

Huiyuan Zhang

http://www.w3.org/2001/XMLSchema#string

Jack Mf Su

http://www.w3.org/2001/XMLSchema#string

Jodi Muscal

http://www.w3.org/2001/XMLSchema#string

Lin Qi

http://www.w3.org/2001/XMLSchema#string

Linna Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease

Aurora-A Kinase as a Promising Therapeutic Target in Cancer

The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study.

A patient tumor-derived orthotopic xenograft mouse model replicating the group 3 supratentorial primitive neuroectodermal tumor in children.

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-2256

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2018-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29463553

http://www.w3.org/2001/XMLSchema#string

P932

6052861

http://www.w3.org/2001/XMLSchema#string